The combination of low-dose regorafenib plus nivolumab exhibited synergistic effect, sensitizing immunotherapy and reducing toxicity in gastric cancer.8 In a patient treated with toripalimab plus anlotinib, the amount of infiltration CD8+ T cells and CD3+ T cells significantly increased in tumor tissue, indicating the combination therapy promoted an immune-supportive environment. Here, CD8A is linked to gastric cancer.